Cleared Traditional

K792062 - THEOPHYLLINE RIASSAY

K792062 is an FDA 510(k) clearance for THEOPHYLLINE RIASSAY, manufactured by Ria Diagnostics. The device is a Class 2 Toxicology device with product code LCA cleared through the Traditional 510(k) pathway after a 133-day FDA review.

K792062 · Ria Diagnostics · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1980
Decision
133d
Days
Class 2
Risk

K792062 is an FDA 510(k) clearance for the THEOPHYLLINE RIASSAY. Classified as Radioimmunoassay, Theophylline (product code LCA), Class II - Special Controls.

Submitted by Ria Diagnostics (Mchenry, US). The FDA issued a Cleared decision on February 25, 1980 after a review of 133 days - within the typical 510(k) review window.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3880 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Ria Diagnostics devices

FDA 510(k) Submission Details - K792062

510(k) Number K792062 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 15, 1979
Decision Date February 25, 1980
Days to Decision 133 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
46d slower than avg
Panel avg: 87d · This submission: 133d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LCA Device Classification - Class 2, Special Controls

Product Code LCA Radioimmunoassay, Theophylline
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3880
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.